We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.

If big pharma was hoping that there would not be drug price negotiations under President Trump, they seem to have had their hopes dashed. That ...

The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process ...

The Biden-era law is now in the hands of a new administration, and drugmakers are scanning the horizon for hints of a massive ...

CMS recently issued a statement saying that it's continuing the Medicare Drug Price Negotiation Program but is leaving the door open for potential changes. Experts weighed in on what changes could be ...

President Trump is likely to embrace the Medicare drug price negotiations that was initiated under the Biden administration, though the president could make some tweaks to put his own spin on it. The ...

The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under ...

Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short ...

President Donald Trump’s Medicare agency is seeking to bring more transparency to the US government’s drug price negotiation ...

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.